Date/Time
Date(s) - 06/30/2022
11:00 AM - 12:00 PM
Categories
Zoom Meeting ID: 979 6297 5142
In-person Location: JABSOM MEB Auditorium
Contact cmlum@hawaii.edu for Zoom passcode
Michael Faundo
MS Candidate
Department of Tropical Medicine, Medical Microbiology and Pharmacology
John A. Burns School of Medicine, University of Hawaii at Manoa
Development of highly effective, broad-spectrum antimicrobial and antiviral agents is a major objective shared by the fields of microbiology,virology and pharmaceutics. Antibiotics have been instrumental I reducing illness and death from microbial infections since the 1940s. However, this widespread use has also led to the advent of multidrug resistance among pathogenic bacteria, with millions dying to infection to such organisms annually. The crisis of antimicrobial resistance has been ascribed to the misuse of these agents and unavailability of newer drugs attributable to demanding regulatory requirements. In contrast, while there are broad-spectrum agents available for antimicrobial uses, the conventional approach for development of antivirals is a ‘one-bug-one-drug’ paradigm. With the growing challenges of emerging and re-emerging viral
pathogens, the present modality is insufficient to address these issues, with few drugs currently available to a prompt control of epidemic viral diseases. While metal compounds have found use as antimicrobial agents, but their antiviral activities have rarely been explored. The focus of this research aims to characterize the potential antimicrobial and antiviral activities of a novel class of organobismuth compounds.